reptides › libido › kisspeptin-10

kisspeptin-10

kisspeptin-family pharmacology with real HSDD and fertility signals. the strongest human trials used kisspeptin-54, not the KP-10 vial market.

tier B · libido · KP-54 strong trials use a different analog

verdict

the kisspeptin family has unusually clean human trial data for sexual medicine and IVF. the strongest trials used kisspeptin-54, not the KP-10 vial market.

if you're asking about the human evidence behind 'kisspeptin' — two double-blind crossover trials at Imperial used kisspeptin-54. not kisspeptin-10. and showed 56% greater penile tumescence in men with HSDD plus fMRI changes in sexual-processing regions in women. the 2025 follow-up confirmed stimulation of reproductive hormones without provoking anxiety. the trial program is small, single-center, phase 1-2. the vial market is selling KP-10. that's not the same molecule the strongest data was generated on.

if you're asking how this compares to PT-141 — different mechanism, different evidence lane. PT-141 hits MC4R centrally and has an FDA-approved label for premenopausal HSDD plus a louder off-label male use case. kisspeptin stimulates endogenous GnRH and modulates sexual-processing brain regions through OXTR-adjacent pathways. kisspeptin is endogenous; PT-141 is synthetic. neither has reached phase 3 for the male PDE5-non-responder lane.

if you came in via the IVF angle — this is the more mature application. kisspeptin-triggered egg maturation cuts ovarian volumes roughly 3x compared to hCG, dramatically reducing OHSS (ovarian hyperstimulation syndrome) risk. that's the closer-to-clinic use case in the kisspeptin pipeline. fertility-clinic adoption is downstream of further regulatory work, not the gray-market vial channel.

based on published evidence and disclosed clinical practice. not medical advice.

why B-tier

B-tier because the clinical research around the kisspeptin pathway is real and rigorous but the regulatory pipeline is still early, and because KP-10 is not the exact molecule used in the strongest HSDD and IVF trials. Imperial College trials give drug-grade evidence at small scale, published in JAMA Network Open, for a clinically meaningful condition. Held back from A by the absence of phase 3 data, no FDA filing pending, and the molecule-identity gap between KP-54 trials and KP-10 market supply.

the core tension

Kisspeptin-family pharmacology has something unusual for a sexual-function peptide: real randomized clinical trials published in JAMA, conducted at Imperial College London with fMRI brain imaging and tumescence measurement. The catch is identity. The headline HSDD and IVF trials used kisspeptin-54, while the market usually sells KP-10. The research is serious, the mechanism is endogenous, and the data are genuinely exciting. The exact gray-market molecule is less proven than the broader kisspeptin signal.

what it is

kisspeptin-10 is the 10-amino-acid C-terminal active fragment of kisspeptin, an endogenous hypothalamic neuropeptide. it is the upstream trigger of the HPG axis: kisspeptin activates GnRH neurons, GnRH releases LH and FSH, which drives testosterone and estrogen. plasma half-life is 4-5 minutes.

what it does

stimulates endogenous GnRH release and modulates sexual-processing brain regions including posterior cingulate cortex, hippocampus, and globus pallidus. in healthy men, IV bolus at 1 mcg/kg produces maximal LH stimulation. continuous infusion raises testosterone from 16.6 to 24.0 nmol/L. effects on women's HPG axis are largely confined to the preovulatory phase.

origin

discovered in 1996 at Pennsylvania State Hershey as a metastasis suppressor and named for Hershey Kisses chocolates. its reproductive role wasn't recognized until 2003, when humans with inactivating KISS1R mutations were shown to fail puberty. the modern clinical research program is led by Prof. Waljit Dhillo at Imperial College London, NIHR-funded, running since roughly 2015.

why researchers are interested

this is one of the few sexual-medicine peptides backed by JAMA Network Open trials with fMRI imaging. it's an endogenous hormone, not a synthetic. the IVF lane is even further along, kisspeptin-triggered egg maturation cuts ovarian volumes roughly 3x compared to hCG, dramatically reducing OHSS risk.

does it work

the kisspeptin-family signal is unusually clean for the space. two double-blind crossover trials at Imperial used kisspeptin-54 and showed 56% greater penile tumescence in men with HSDD plus fMRI changes in sexual-processing regions in women. a 2025 study confirmed kisspeptin stimulates reproductive hormones without provoking anxiety, useful de-risking. but everything is small, single-center, and phase 1-2. the IVF program is the closer mature application; the HSDD pipeline is exciting but no phase 3, no filing, no approval. promising, not proven, and not a clean proof of gray-market KP-10.

claims vs the data

  • improves sexual brain processing in HSDD — supported — Two JAMA Network Open trials with 32 women and 32 men used kisspeptin-54 infusion. fMRI confirmed activity changes in sexual-processing regions compared to placebo. Peer-reviewed, double-blind, crossover design. Real clinical evidence for the kisspeptin pathway.
  • increases penile tumescence in men with HSDD — supported — 56% increase vs placebo in the 2023 men's kisspeptin-54 trial. Measured objectively via penile tumescence device during 8-minute sexual video. Effect size large and statistically significant.
  • safer than existing HSDD treatments — partially true — Phase 1-2 trials show excellent safety profile, no serious adverse events across multiple studies at Imperial. Most common effect is transient flushing. But existing treatments (flibanserin, bremelanotide) have known side effect profiles from phase 3 and long-term data. Kisspeptin hasn't been tested at that scale yet.
  • works for both men and women — supported — Separate JAMA Network Open trials in men and women with HSDD showed effects in both populations, though through slightly different brain pathways. This is unusual for a sexual medicine compound and genuinely novel.
  • can replace hCG as an IVF trigger with lower OHSS risk — supported — Multiple Imperial College trials have tested kisspeptin-54 as an IVF trigger. Produces egg maturation with approximately 3x smaller ovarian volume than hCG, dramatically reducing ovarian hyperstimulation syndrome risk in those protocols. This is KP-54 clinical evidence, not proof that KP-10 research vials reproduce the same result.
  • FDA-approved for any sexual function indication — contradicted — No FDA approval exists. No filing is currently pending. Development is at phase 1-2 and will need phase 3 before any approval path. Current use outside research is off-label research-peptide use.

key facts

  • molecular formula: C63H83N17O14
  • molecular weight: 1302.5 Da
  • amino acids: 10 (active C-terminal fragment of kisspeptin-54)
  • half-life: short, approximately 4-5 minutes in plasma (full kisspeptin-54 is the longer-acting parent)
  • type: neuropeptide hormone fragment (GnRH cascade trigger)
  • CAS: 374675-21-5
  • 56% increase in penile tumescence vs placebo (HSDD trial)
  • 32+32 men and women enrolled in JAMA trials
  • 2023 JAMA Network Open publication of HSDD trials
  • Phase 1-2 current clinical development stage

frequently asked questions

What is Kisspeptin-10?

Kisspeptin-10 is a 10-amino-acid active fragment of the parent kisspeptin protein. Kisspeptin is the master upstream regulator of the hypothalamic-pituitary-gonadal (HPG) axis, the signal that triggers GnRH release, which in turn drives the entire reproductive hormone cascade.

What does Kisspeptin-10 do?

Stimulates endogenous GnRH release, which drives the downstream cascade of LH and FSH release from the pituitary and subsequently testosterone or estrogen production from the gonads. Used in clinical research to probe HPG axis function and in fertility diagnostics. Community use targets HPG axis restart or fertility support.

How is Kisspeptin-10 typically administered?

Clinical research uses controlled IV infusion for HPG-axis testing, while the strongest HSDD and IVF trials used kisspeptin-54 rather than KP-10. Research-peptide market routes do not map cleanly to those trial regimens, and there is no FDA-approved administration protocol.

What are the side effects of Kisspeptin-10?

Reported side effects in clinical research are minimal, occasional flushing, mild headache, injection-site reactions. The downstream hormonal effect (HPG axis stimulation) is pharmacologically robust and any concerns are primarily around over-stimulation rather than direct toxicity.

Is Kisspeptin-10 FDA approved?

No. Kisspeptin-10 has no FDA approval. It is used in clinical research and early-stage pharmaceutical development for fertility and HPG axis disorders, with no approved therapeutic indication at this time.

How much does Kisspeptin-10 cost?

No clinical retail price exists. Unregulated research-chemical listings circulate, but product identity, purity, and dose are not verified on that channel.

related peptides

  • pt-141 — other main peptide pipeline for sexual desire, different mechanism (melanocortin)
  • oxytocin — social/pair-bonding peptide with overlapping research communities
  • hcg — another reproductive-axis hormone used therapeutically

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.